tetano
Editor, Senior Moderator
Obstet Gynecol
. 2025 Dec 11.
doi: 10.1097/AOG.0000000000006145. Online ahead of print. Effectiveness of 2023-2024 Coronavirus Disease 2019 (COVID-19) Vaccines in Pregnant Women
Allison Avrich Ciesla[SUP] 1 [/SUP], Victoria Lazariu, Janet A Watts, Gabriela Vazquez-Benitez, Kristin Dascomb, Stephanie A Irving, Nicola P Klein, Shaun J Grannis, Toan C Ong, Sarah W Ball, Malini DeSilva, Tamara Sheffield, Daniel Bride, Joshua Van Otterloo, Julie Arndorfer, Allison L Naleway, Padma Koppolu, Bruce Fireman, John Hansen, Julius Timbol, Brian E Dixon, Colin Rogerson, William Fadel, Michelle A Barron, David Mayer, Catia Chavez, Yan Zhuang, Angela Cheung, Lawrence Reichle, Karthik Natarajan, Amanda B Payne, Ruth Link-Gelles, Ousseny Zerbo
Affiliations
Pregnant women are at higher risk of severe coronavirus disease 2019 (COVID-19) compared with nonpregnant women of reproductive age. During 2023-2024, the Centers for Disease Control and Prevention recommended COVID-19 vaccination for everyone aged 6 months or older, including pregnant women. Using a test-negative design, we assessed the effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated emergency department (ED) and urgent care setting encounters among pregnant women aged 18-45 years presenting for care with COVID-19 symptoms from September 2023 to August 2024. Vaccine effectiveness against COVID-19-associated ED and urgent care encounters of one 2023-2024 COVID-19 vaccine dose was 58% (95% CI, 24-77%) among pregnant women and 37% (95% CI, 29-44%) among nonpregnant women of the same age. The 2023-2024 COVID-19 vaccines were associated with a decrease in COVID-19-associated ED and urgent care encounters among pregnant women and nonpregnant women of reproductive age.
. 2025 Dec 11.
doi: 10.1097/AOG.0000000000006145. Online ahead of print. Effectiveness of 2023-2024 Coronavirus Disease 2019 (COVID-19) Vaccines in Pregnant Women
Allison Avrich Ciesla[SUP] 1 [/SUP], Victoria Lazariu, Janet A Watts, Gabriela Vazquez-Benitez, Kristin Dascomb, Stephanie A Irving, Nicola P Klein, Shaun J Grannis, Toan C Ong, Sarah W Ball, Malini DeSilva, Tamara Sheffield, Daniel Bride, Joshua Van Otterloo, Julie Arndorfer, Allison L Naleway, Padma Koppolu, Bruce Fireman, John Hansen, Julius Timbol, Brian E Dixon, Colin Rogerson, William Fadel, Michelle A Barron, David Mayer, Catia Chavez, Yan Zhuang, Angela Cheung, Lawrence Reichle, Karthik Natarajan, Amanda B Payne, Ruth Link-Gelles, Ousseny Zerbo
Affiliations
- PMID: 41380159
- DOI: 10.1097/AOG.0000000000006145
Pregnant women are at higher risk of severe coronavirus disease 2019 (COVID-19) compared with nonpregnant women of reproductive age. During 2023-2024, the Centers for Disease Control and Prevention recommended COVID-19 vaccination for everyone aged 6 months or older, including pregnant women. Using a test-negative design, we assessed the effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated emergency department (ED) and urgent care setting encounters among pregnant women aged 18-45 years presenting for care with COVID-19 symptoms from September 2023 to August 2024. Vaccine effectiveness against COVID-19-associated ED and urgent care encounters of one 2023-2024 COVID-19 vaccine dose was 58% (95% CI, 24-77%) among pregnant women and 37% (95% CI, 29-44%) among nonpregnant women of the same age. The 2023-2024 COVID-19 vaccines were associated with a decrease in COVID-19-associated ED and urgent care encounters among pregnant women and nonpregnant women of reproductive age.